Table 2.
Univariate analysis of factors associated with survival and progression.
| Variables | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| n | HR | 95% CI | p * | n | HR | 95% CI | p * | |
| Age | ||||||||
| ≥60 years vs. <60 years | 76 | 1.827 | 1.040–3.210 | 0.0359 | 95 | 1.989 | 1.195–3.308 | 0.0093 |
| Resection degree | 76 | 0.3289 | 95 | <0.0001 | ||||
| Biopsy vs. Partial | 39 | 1.521 | 0.646–3.579 | 0.3367 | 54 | 7.764 | 3.344–18.170 | <0.0001 |
| Biopsy vs. Macroscopic | 47 | 2.113 | 0.848–5.265 | 0.1084 | 61 | 9.925 | 3.900–21.820 | <0.0001 |
| Partial vs. Macroscopic | 66 | 1.150 | 0.682–1.940 | 0.5995 | 75 | 1 | 0.598–1.672 | 0.9996 |
| RPA | 76 | 0.1596 | 95 | 0.0120 | ||||
| ≥V vs. <V | 59 | 1.560 | 0.868–2.803 | 0.1367 | 74 | 2.106 | 1.230–3.607 | 0.0066 |
| P53 gene status | 76 | 0.7537 | 95 | 0.8356 | ||||
| Mutated vs. Non Mutated | 15 | 0.597 | 0.151–2.360 | 0.4622 | 18 | 0.597 | 0.128–2.784 | 0.5118 |
| MGMT promoter status | 76 | 0.0834 | 95 | 0.0690 | ||||
| Un-Methylated vs. Methylated (All) | 47 | 2.194 | 1.135–4.243 | 0.0195 | 59 | 2.217 | 1.184–4.151 | 0.0129 |
| Un-Methylated vs. Methylated (Stupp) | 45 | 2.547 | 1.292–5.021 | 0.0069 | 53 | 2.497 | 1.278–4.880 | 0.0074 |
| Un-Methylated vs. Methylated (Completed Stupp) | 31 | 2.083 | 0.926–4.682 | 0.0759 | 35 | 2.062 | 0.872–4.872 | 0.0992 |
| Integrin α5 | ||||||||
| High vs. Low expression (All) | 76 | 1.696 | 1.031–2.792 | 0.0377 | 95 | 1.598 | 0.998–2.558 | 0.0508 |
| High vs. Low expression (Stupp) | 72 | 1.771 | 1.055–2.975 | 0.0307 | 83 | 1.805 | 1.106–3.096 | 0.0191 |
| High vs. Low expression (Completed Stupp) | 53 | 1.635 | 0.879–3.040 | 0.1206 | 58 | 2.324 | 1.168–4.621 | 0.0162 |
PFS: progression-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval; y: year; RPA: recursive partitioning analysis; MGMT: O-6-methylguanine-DNA methyltransferase. * log-rank test, p < 0.05 was considered as significant.